Eloxx Pharmaceuticals Dividendos y recompras

Dividendo controles de criterios 0/6

Eloxx Pharmaceuticals no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-162,900,000.0%

Rendimiento de la recompra

Rendimiento total para el accionista	-162,900,000.0%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

Jan 13

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ELOX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ELOX han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Eloxx Pharmaceuticals vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de ELOX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (ELOX)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Pharmaceuticals)	2.4%
Analista de previsiones (ELOX) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ELOX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ELOX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de ELOX para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ELOX no ha comunicado ningún pago.

Eloxx Pharmaceuticals Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Nasdaq to Delist Common Stock of Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals Receives a Determination Letter from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013

New minor risk - Shareholder dilution

Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Nasdaq Grants Extension to Eloxx Pharmaceuticals to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

New major risk - Market cap size

Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Receives Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome

Price target increased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives Written Notification Letter from the Listing Qualifications Department of Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Price target decreased to US$2.25

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Price target decreased to US$3.00

Eloxx Pharmaceuticals Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President exercised options and sold US$59k worth of stock

Price target increased to US$4.03

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

COO, General Counsel & Corporate Secretary Neil Belloff has left the company

Executive Director of Finance & Accounting, Corporate Controller and Treasurer Gary Rakers has left the company

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell 3000E Index

Eloxx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $45.000001 million.

Eloxx Pharmaceuticals EPS misses by $0.06

Independent Director has left the company

CEO & Director Gregory Williams has left the company

Founder & Director Silvia Noiman has left the company

VP of Finance & Accounting, Principal Financial & Accounting Officer and Treasurer has left the company

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Eloxx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 11, 2021

CEO & Director exercised options and sold US$61k worth of stock

New 90-day high: US$4.51

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The Cystic Fibrosis Foundation Awards upto $2 Million to Eloxx Pharmaceuticals Inc. for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

New 90-day high: US$3.94

New 90-day low: US$2.42

Eloxx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.68

Eloxx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell Microcap Value Index

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos